WASHINGTON, July 10, 2003 (PRIMEZONE) -- Growth Report, an independent investment newsletter service for individual investors that has delivered returns of 48.6% in the first half of 2003, today announced the addition of Medifast (AMEX:MED) to its stock portfolio.
Medifast develops, manufactures and distributes high quality weight and disease management, sports nutrition, and other consumable health products.
Growth Report added Medifast to the model portfolio on July 9 at $12.71. This initial research report is available on the Growth Report web site free of charge to trial subscribers at http://www.growthreport.com/
The report discusses:
-- Obesity and health problems facing Americans as a result of being
overweight
-- The solutions offered by Medifast
-- Market trends for weight loss and weight management products
-- Potential growth for the sector and Medifast
In the July 9th issue of Growth Report, Editor Ian Wyatt wrote, "Medifast clearly fits the bill as a small cap growth stock in a healthy sector of the market. Medifast still remains largely unknown in our opinion. Institutional ownership is nil at this point. We believe with the high growth rates being delivered by Medifast, it is only a matter of time before more individuals and institutions catch wind of the company's story and begin buying up shares."
Medifast competes in this $26 billion market with many companies including Weight Watchers (NYSE: WTW), Hi-Tech Parmacal (Nasdaq: HITK), and Natures Sunshine Products (Nasdaq: NATR). Medifast reported stellar revenue and earnings growth rates in recent quarters.
Growth Report's stock portfolio returned 40% in 2002, and is up another 48.6% in the first half of 2003 by taking long-term positions in fundamentally strong growth stocks. This investment approach had yielded consistently strong returns for subscribers of the newsletter service.
Individual investors who are interested in signing up for a 30-day free trial to Growth Report will receive this report on Medifast, plus a free Special Report titled "Not So Generic Returns -- Investing in Generic and Specialty Pharmaceuticals." Free trial subscribers also receive two issues per week by e-mail, one issue per month in print, access to over one year of archived articles, and past and future Special Reports. To start a free 30-day trial subscription, click here: https://www.bizfn.com/index.cfm?Page=pubs&pubs=2&r=pr4
About Growth Report
Growth Report is a leading investment newsletter service published by Business Financial Publishing, LLC. Growth Report is entirely independent, and dedicated to uncovering stocks that will deliver the greatest return to subscribers. Two weekly issues delivered by e-mail and on the web provide subscribers with regular updates on the latest news and changes to the portfolio, while a monthly print edition provides in depth articles in an easy to read format.
Disclaimer
Growth Report is neither a registered investment advisor nor a broker / dealer. Readers are advised that the publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. No information provided herein or elsewhere from Growth Report constitutes a recommendation by Growth Report to buy, sell or hold any security. We encourage you to consult with independent financial advisors with respect to any investment in the securities mentioned herein.